About Phathom Pharmaceuticals
Phathom Pharmaceuticals is a company based in Menlo Park (United States) founded in 2019 by David Socks. Phathom Pharmaceuticals has raised $90 million across 2 funding rounds from investors including SVB, Janus Henderson Investors and RA Capital. The company has 427 employees as of December 31, 2024. Phathom Pharmaceuticals offers products and services including VOQUEZNA. Phathom Pharmaceuticals operates in a competitive market with competitors including VectivBio, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Kamui Pharma and Ellodi Pharmaceuticals, among others.
- Headquarter Menlo Park, United States
- Employees 427 as on 31 Dec, 2024
- Founders David Socks
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Phathom Pharmaceuticals, Inc.
-
Annual Revenue
$55.25 M (USD)8001.47as on Dec 31, 2024
-
Net Profit
-$334.33 M (USD)-65.84as on Dec 31, 2024
-
EBITDA
-$276.67 M (USD)-65.93as on Dec 31, 2024
-
Total Equity Funding
$90 M (USD)
in 2 rounds
-
Latest Funding Round
$90 M (USD), Series C
May 15, 2019
-
Investors
SVB
& 9 more
-
Employee Count
427
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Phathom Pharmaceuticals
Phathom Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol PHAT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Phathom Pharmaceuticals
Phathom Pharmaceuticals offers a comprehensive portfolio of products and services, including VOQUEZNA.
Treats acid-related damage and heartburn for GI disorders in adults.
People of Phathom Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Phathom Pharmaceuticals
Phathom Pharmaceuticals has successfully raised a total of $90M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $90 million completed in May 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Phathom Pharmaceuticals
Phathom Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include SVB, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage life science focused VC firm investing in geographies such as Europe and the US
|
Locked | Locked | Locked | |
|
Early stage venture capital firm investing in US
|
Locked | Locked | Locked | |
|
Diversified investment management firm
|
Locked | Locked | Locked |
Investor details for Phathom Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Phathom Pharmaceuticals
Investment portfolio details for Phathom Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Phathom Pharmaceuticals
Detailed financials for Phathom Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Phathom Pharmaceuticals Comparisons
Peer comparison for Phathom Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Phathom Pharmaceuticals
Phathom Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as VectivBio, Guangzhou Zhiyi Pharmaceutics, Lumena Pharma, Kamui Pharma and Ellodi Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Transformative therapeutics for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Second-generation probiotics are developed for gastrointestinal disorders.
|
|
| Locked | Locked | Locked |
Passionately pursuing better treatments for adults and children with rare liver diseases.
|
|
| Locked | Locked | Locked |
Probiotic medicines for treating gastrointestinal diseases are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for Eosinophilic Esophagitis are developed by Ellodi Pharmaceuticals.
|
Detailed competitors of Phathom Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Phathom Pharmaceuticals
Complete news archive for Phathom Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Phathom Pharmaceuticals
Phathom Pharmaceuticals was founded in 2019.
Phathom Pharmaceuticals is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
David Socks is the current CEO of Phathom Pharmaceuticals. They have also founded this company.
Phathom Pharmaceuticals is a funded company, having raised a total of $90M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Phathom Pharmaceuticals is 427.
Annual revenue of Phathom Pharmaceuticals is $55.25M as on Dec 31, 2024.
Phathom Pharmaceuticals was founded in 2019 and is based in Menlo Park, United States. Operations are centered in the pharmaceutical sector, where gastrointestinal disease treatments are developed. The lead candidate, Vonoprazana potassium-competitive acid blockeris targeted at gastroesophageal reflux disease and erosive esophagitis, with phase II clinical trials completed. Leadership includes David Socks as co-founder and CEO, alongside Terrie Curran as CEO and president.
Phathom Pharmaceuticals's top competitors include VectivBio, Lumena Pharma and Guangzhou Zhiyi Pharmaceutics.
Phathom Pharmaceuticals offers VOQUEZNA.
Yes, Phathom Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol PHAT.
Phathom Pharmaceuticals has 10 investors. Key investors include SVB, Janus Henderson Investors, RA Capital, Frazier Healthcare Partners, and Abingworth.
The ticker symbol of Phathom Pharmaceuticals is PHAT on NASDAQ.